MetaCap

Neumora Therapeutics Inc. (NMRA)

NASDAQ: NMRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.3339-0.0131 (-3.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NMRA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$63.01M
EPS (TTM)
-$1.06
52-week range
0.301 – 3.65
Day range
0.3011 – 0.3599
Volume / Avg
1.06M / 1.69M
Beta
—

52-week range

$0.301$3.65

NMRA stock today

On Nov 20, NMRA ended the session at $0.3339, shedding $0.0131 (3.78%), versus the S&P 500's 3.70% decline. At this level, NMRA sits near the bottom of its 52-week range of $0.301 to $3.65: 90.9% below the high, set on Feb 18, 2026 and 10.9% above the low. NMRA is down 81.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.7%.

Neumora Therapeutics has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neumora Therapeutics

Company profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Joshua Pinto Ph.D.
Headquarters
Watertown, MA
Employees
63
IPO year
2023

Financial highlights

Full financials

Neumora Therapeutics reported a net loss of $236.9 million, compared with a loss of $243.8 million a year earlier. Diluted earnings per share came in at -$1.45.

Neumora Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-236.93M$-243.79M$-235.93M$-130.90M
EPS (diluted)$-1.45$-1.53$-3.63$-4.81

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$6.00+1696.95%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $3.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.18 vs $-0.19
Surprise
+5.26%

NMRA news

All NMRA news

Neumora Therapeutics peers

Health Care sector
NMRA peer companies
CompanyPrice% ChgMarket capCompare
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs NMRA
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs NMRA
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs NMRA
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs NMRA
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs NMRA
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs NMRA
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs NMRA
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs NMRA

Indexes, lists and sector

Neumora Therapeutics stock FAQ

What is Neumora Therapeutics's stock price today?

NMRA last traded at $0.3339 as of Nov 20, 4:00 PM EST, down 3.78% on the day. Prices are delayed at least 15 minutes.

Who is Neumora Therapeutics's CEO?

Dr. Joshua Pinto Ph.D. is the chief executive officer of Neumora Therapeutics Inc., which has about 63 employees.

What is the NMRA 52-week high?

The 52-week high for NMRA is $3.65 and the 52-week low is $0.301. The stock is currently 90.9% below its high.

Compare NMRA